Generic placeholder image

Current Psychopharmacology

Editor-in-Chief

ISSN (Print): 2211-5560
ISSN (Online): 2211-5579

Case Report

Low-Dose Lithium for Long-Term Treatment of Clozapine- Induced Neutropenia: A Case Series

Author(s): Muhammad R. Baig*

Volume 8 , Issue 2 , 2019

Page: [155 - 158] Pages: 4

DOI: 10.2174/2211556008666190130165540

Abstract

Background: Treatment-resistant psychosis makes schizophrenia a disabling and costly illness. Clozapine is an effective treatment for treatment-resistant psychosis, though it is underutilized mainly due to prescribing providers’ fear of a serious yet uncommon complication, clozapine-induced neutropenia. Clozapine-induced neutropenia predisposes patients to potentially life-threatening infections leading prescribers to stop use when blood counts start to drop even well above the recommended cut-off point. Colonystimulating factors are effective options for reducing risk and duration of neutropeniarelated events though they add a significant cost burden to the patient and healthcare system. There is a great need for feasible and cost-effective pharmacotherapies in the mental health care setting for the management of clozapine-induced neutropenia.

Objective: We evaluated adjunctive use of lithium when prescribed at a low-dose to stabilize dropping blood count in patients receiving clozapine for treatment-resistant psychosis.

Methods & Results: A case series analysis of three patients who were followed in a mental health outpatient clinic for the management of schizophrenia. Blood counts of all the patients were stabilized by low-dose lithium treatment and continued to receive long term treatment of clozapine.

Conclusion: Results suggest low-dose lithium as a feasible and cost-effective pharmacotherapeutic option enabling the continuation of clozapine, an effective treatment for treatment-resistant psychosis.

Keywords: Clozapine-induced neutropenia, long-term stabilization, psychopharmacotherapy, treatment resistant psychosis, blood count, schizophrenia.

[1]
Sartorius N, Shapiro R, Kimura M, Barrett K. WHO International pilot study of schizophrenia. Psychol Med 1972; 2(4): 422-5.
[2]
Jin H, Mosweu I. The societal cost of schizophrenia: a systematic review. Pharmacoeconomics 2017; 35(1): 25-42.
[3]
Andrade C. Antipsychotic drugs in schizophrenia: relative effects in patients with and without treatment resistance. J Clin Psychiatry 2016; 77(12): e1656-60.
[4]
Meltzer HY. Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin 1997; 14(1): 1-20.
[5]
Porcelli S, Balzarro B and, Serretti B. Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol 2012; 22(3): 165-82.
[6]
Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329(3): 162-7.
[7]
Focosi D, Azzara A, Kast RE, Carulli G, Petrini M. Lithium and hematology: established and proposed uses. J Leukoc Biol 2009; 85(1): 20-8.
[8]
Wijeratne C, Draper B. Reformulation of current recommendations for target serum lithium concentration according to clinical indication, age and physical comorbidity. Aust N Z J Psychiatry 2011; 45(12): 1026-32.
[9]
Spencer BW, Williams HR, Gee SH, et al. Granulocyte colony stimulating factor (G-CSF) can allow treatment with clozapine in a patient with severe benign ethnic neutropaenia (BEN): a case report. J Psychopharmacol 2012; 26(9): 1280-2.
[10]
Silverstone PH. Prevention of clozapine-induced neutropenia by pretreatment with lithium. J Clin Psychopharmacol 1998; 18(1): 86-8.
[11]
Gupta S. First-generation vs second-generation antipsychotic drugs: The ongoing saga. Indian J Psychiatry 2010; 52(1): 77.
[12]
Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol 2013; 16(6): 1205-18.
[13]
Agid O, Arenovich T, Sajeev G. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 2011; 72(11): 1439-44.
[14]
Atkinson JM, Douglas-Hall P, Fischetti C, Sparshatt A, Taylor DM. Outcome following clozapine discontinuation: a retrospective analysis. J Clin Psychiatry 2007; 68(7): 1027-30.
[15]
Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 2006; 114(1): 3-13.
[16]
Rettenbacher MA, Hofer A, Kemmler G, Fleischhacker WW. Neutropenia induced by second generation antipsychotics: a prospective investigation. Pharmacopsychiatry 2010; 43(2): 41-4.
[17]
Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses 2012; 6(3): 134-44.
[18]
Gopalakrishnan R, Subhalakshmi TP, Kuruvilla A, Jacob KS. Clozapine re-challenge under the cover of Filgrastim. J Postgrad Med 2013; 59(1): 54-5.
[19]
Friedenberg WR, Marx Jr J.J.. The effect of lithium carbonate on lymphocyte, granulocyte, and platelet function. Cancer 1980; 45(1): 91-7.
[20]
Kanaan RA, Kerwin RW. Lithium and clozapine rechallenge: a retrospective case analysis. J Clin Psychiatry 2006; 67(5): 756-60.
[21]
Palominao A, Kukoyi O, Xiong G. Leukocytosis after lithium and clozapine combination therapy. Ann Clin Psychiatry 2010; 22(3): 205-6.

© 2022 Bentham Science Publishers | Privacy Policy